NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger…
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July…
Read More...
Read More...
Browsing Tag
IMCIVREE
Rhythm Pharmaceuticals schließt die Einreichung des Antrags für die Typ-II-Variation für IMCIVREE ®…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches…
Read More...
Read More...
Rhythm Pharmaceuticals completa la presentazione della domanda di variazione tipo II…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in…
Read More...
Read More...
Rhythm Pharmaceuticals completa la presentación de la solicitud de variación de tipo II a la Agencia…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en…
Read More...
Read More...